Navigation Links
Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Date:6/1/2010

CAMBRIDGE, Mass., June 1 /PRNewswire/ -- Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference in New York City. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 11:00am EDT, Wednesday, June 9, 2010 at the Grand Hyatt in New York City, New York.

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack's first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contacts

Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli@merrimackpharma.com, http://www.merrimackpharma.com

Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
10. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
11. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family Foundation ... six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. Established ... administered by the New York Academy of Sciences to honor the excellence of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... United States multicenter, prospective clinical study that demonstrates the accuracy of the ... of identifying clinically significant acute bacterial and viral respiratory tract infections by ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):